To view this email as a web page, click here.
 
OUR SEPTEMBER ISSUE IS NOW LIVE
 
Urology Times cover
View the latest issue online.
How to improve patients’ access to their health information
“Practices who have not yet mastered the art of registering all patients for portal access are simply not meeting the expectation of most patients and payers—including Medicare—and will see this reflected in their MIPS scores this performance year,” writes Robert A. Dowling, MD.
Read his column
 
Uro Pipeline: Hyperoxaluria agent shows substantial treatment effect
Consistent with Allena Pharmaceuticals’ prior clinical experience, enteric hyperoxaluria patients treated with reloxaliase in Study 206 demonstrated a substantial treatment effect.
Learn more
 
SURVEY
 
Is DRE still a relevant tool in the management of prostate cancer?
 
MORE FROM UROLOGY TIMES
 
Prostate-sparing treatment using nanoparticles shows promise
What’s your biggest frustration with prior authorization?
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.